保肝延年注射液抗肝癌作用的实验研究

Experimental Studies of Anti-tumor Effect of Baoganyannian Injection on Liver Cancer

目的研究保肝延年注射液的抗肝癌作用。方法选择小鼠肝癌H22癌模型、MTT法和集落形成法,观察保肝延年注射液对荷瘤鼠和人肝癌SMMC-7721细胞株的作用。结果腹腔注射保肝延年注射液80mg/kg、160mg/kg、320mg/kg,肿瘤受到明显抑制,抑制率分别为72.5%、90.1%和94.6%(P<0.05,P<0.01);小鼠生存时间显著延长;在体外保肝延年注射液对人肝癌细胞有明显的细胞毒作用,其IC50为2.04μg/ml;同时保肝延年注射液可抑制人肝癌SMMC-7221克隆原细胞形成集落,其IC50为2.35μg/ml。结论保肝延年注射液在体内和体外均具有抗肝癌作用。

Objective to investigate the anti-hepatocarnicinoma effect of Baoganyannian injection. Methods The mice bearing H22 solid and ascitic liver tumor were applied in vivo experiments. Microculture tetrazolium assay and colony-forming unit assay were applied to test the cytotoxicity to human hepatocarcinoma SMMC-7221 cell line in vitro. Results The growth of solid tumor was obviously inhibited by Baoganyannian injection at the dose of 80mg/kg, 160 mg/kg and 320 mg/kg ip for 7 days. The tumor inhibiting rates are 72.5%, 90. 1% and 94.6%respectively. After administration of Baoganyannian injection, the survivals rate of the mice bearing H22 ascitic liver tumor increased to 50.19%,73.45% and 80.68% in three groups. Compared with the control group, the differences are significant（P〈0.05,P〈0.01）.In addition, Baoganyannian injection showed evident cytotoxicity in human hepatocarcinoma SMMC-7221 cells, the IC50 bearing 2.04 μg/ml in MTT experiment and 2.35μ g/ml in colony-forming unit experiment. Conclusion Baoganyannian injection has marked anti-hepatocarcinoma effect in vitro and in vivo.